ACCESS TO MEDICINES /
OUR INTERNATIONAL WORK
WE SOUGHT JUSTICE FOR TOBEKA DAKI, WHO DIED AS A RESULT OF NOT BEING ABLE TO AFFORD NECESSARY TREATMENT
In November 2016, South African Tobeka Daki died after years of fighting breast cancer, unable to access the drug she needed due its high price. Meanwhile, Roche, the company that sells the drug that Tobeka could never access, was fighting to prevent more generic versions of the product from entering the market.
The drug, Herceptin, reaches prices in South Africa of $38,000 in the private sector and almost $16,000 in the public. In Spain, it is around 30,000 euros per treatment. Tobeka was another victim of greedy pharmaceutical companies, which are increasingly setting higher prices for their newest cancer drugs. A very worrisome upward trend that leaves thousands of patients around the world without treatment, putting their health and lives at risk.
In a letter, together with more than 100 organizations, we asked for justice for Tobeka. In addition, we published her story in eldiario.es.
The drug, Herceptin, reaches prices in South Africa of $38,000 in the private sector and almost $16,000 in the public. In Spain, it is around 30,000 euros per treatment. Tobeka was another victim of greedy pharmaceutical companies, which are increasingly setting higher prices for their newest cancer drugs. A very worrisome upward trend that leaves thousands of patients around the world without treatment, putting their health and lives at risk.
In a letter, together with more than 100 organizations, we asked for justice for Tobeka. In addition, we published her story in eldiario.es.